LIFE News and Press, aTyr Pharma Inc. From 12/12/19

Thinly traded nano cap aTyr Pharma (NASDAQ: LIFE ) is down  17%  premarket on increased volume, 65K shares, in reaction to its announcement  of safety and tolerability results from a multiple-ascending dose Phase 1b/2a clinical trial evaluating lead candidate ATYR1923 in pati...

ATYR1923 safe and well tolerated in initial 15 randomized patients with pulmonary sarcoidosis No drug-related serious adverse events observed SAN DIEGO, Dec. 12, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and de...

aTyr Pharma, Inc. (LIFE) Q3 2019 Earnings Conference Call November 14, 2019 05:00 PM ET Company Participants Jill Broadfoot - CFO Sanjay Shukla - President and CEO Conference Call Participants Shawn Egan - Citi Joseph Pantginis - H.C. Wainwright Robert LeBoyer - Ladenburg...

aTyr Pharma (NASDAQ: LIFE ): Q3 GAAP EPS of -$1.47 beats by $0.26 . More news on: aTyr Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients due in December 2019 Company to host conference call and webcast today, November 14, at 5:00pm EDT SAN DIEGO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ...

SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Dr. Sanjay Shukla, President and Chief Executive Officer of a...

SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report third quarter 2019 results after the market cl...

TrovaGene (NASDAQ: TROV ) +56%  on positive response to treatment in phase 1b/2 trial of onvansertib in patients with KRAS-mutated metastatic colorectal cancer. More news on: TrovaGene, Inc., Biogen Inc., Stamps.com Inc., Stocks on the move, Read more ...

SAN DIEGO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company has entered into a research collaboration with Bo...

SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will be participating in two investor conference...